Tudor Investment Corp’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Tudor Investment Corp’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$81.5K	Hold	34,849	–	–	﹤0.01%	3470
2025 Q4	$47K	Hold	34,849	–	–	﹤0.01%	3398
2025 Q3	$52.6K	Hold	34,849	–	–	﹤0.01%	3279
2025 Q2	$40.4K	Hold	34,849	–	–	﹤0.01%	3168
2025 Q1	$55.4K	Sell	34,849 -320	-0.9%	-$690	﹤0.01%	2955
2024 Q4	$107K	Sell	35,169 -540	-2%	-$1.77K	﹤0.01%	2904
2024 Q3	$131K	Buy	+35,709	New	+$130K	﹤0.01%	2573
2024 Q2	–	Sell	-35,303	Closed	-$556K	–	2876
2024 Q1	$556K	Buy	+35,303	New	+$486K	﹤0.01%	1608
2023 Q4	–	Sell	-35,225	Closed	-$707K	–	2981
2023 Q3	$707K	Buy	+35,225	New	+$894K	0.01%	1498
2023 Q1	–	Sell	-20,054	Closed	-$404K	–	3032
2022 Q4	$404K	Buy	+20,054	New	+$431K	0.01%	1726
2022 Q2	–	Sell	-15,531	Closed	-$717K	–	2585
2022 Q1	$717K	Sell	15,531 -7,610	-33%	-$411K	0.02%	1066
2021 Q4	$1.95M	Buy	+23,141	New	+$1.79M	0.03%	643
2020 Q4	–	Sell	-37,628	Closed	-$1.23M	–	1674
2020 Q3	$1.23M	Buy	+37,628	New	+$1.32M	0.05%	497

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Tudor Investment Corp's ZNTL Position: Q1 2026 in Review

Tudor Investment Corp held its Zentalis Pharmaceuticals (ZNTL) position steady in Q1 2026 at 34,849 shares worth $81.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3470.

Tudor Investment Corp first reported a position in ZNTL in Q3 2020 and has held it in 13 quarters since. The position peaked at $1.95M in Q4 2021. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

Tudor Investment Corp held 34,849 shares of Zentalis Pharmaceuticals worth $81.5K as of Q1 2026.
Tudor Investment Corp left its Zentalis Pharmaceuticals share count unchanged in Q1 2026.
Zentalis Pharmaceuticals made up ﹤0.01% of Tudor Investment Corp's portfolio in Q1 2026, its #3470 holding.
Tudor Investment Corp first reported a position in Zentalis Pharmaceuticals in Q3 2020 and has held it in 13 quarters since.
Tudor Investment Corp's Zentalis Pharmaceuticals position peaked at $1.95M in Q4 2021.
102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.